BioBridgeX
Log inCompare quotes
Discovery

Target ID & Validation CROs

Free for buyersNeutral marketplace
Quick answer

Target ID and validation is the earliest discovery work, where a CRO proves a gene or protein actually drives a disease and is worth drugging before you spend on screening or chemistry. It uses CRISPR knockout, RNAi knockdown, genetic association, and pathway evidence. On BioBridgeX, buyers source and compare qualified CROs and contract directly with the one they choose, free for buyers.

Target ID & Validation CROs on BioBridgeX

We are qualifying and publishing Target ID & Validation CROs now. Tell us what you need and we will match you with vetted vendors, or list your organization to be among the first.

What is Target ID and validation, and when do you need it?

Target identification and validation is the first real fork in a drug program. Target ID is finding the gene, protein, or pathway that plausibly drives a disease. Validation is the harder, more expensive half: building enough evidence that hitting that target will change the disease, and that it is druggable, before you commit a budget to assays, screening, and chemistry. Get this wrong and everything downstream inherits the mistake, which is why so much of clinical attrition traces back to targets that were never properly de-risked.

You need this work at the very start of discovery, when you have a disease biology hypothesis but no validated point of intervention yet. Sometimes it is a fresh target nobody has drugged. Sometimes it is a target a competitor is chasing and you want independent confirmation before you follow. Either way the question is the same: does perturbing this target move the biology you care about, in a model that means something, and is there a realistic way to drug it. A CRO running CRISPR knockout and knockdown, RNAi, and target-engagement readouts answers the first part; genetic association and human evidence answers whether the link holds in people, not just a cell line.

The practical reason to validate hard here is cost asymmetry. A target-validation package is a few months of focused work against a screening campaign and years of chemistry that follow. Spending properly on validation, and being willing to kill a target that does not hold up, is the cheapest risk reduction available in the whole development chain. Most of this is research-grade, non-GLP science, so you are buying scientific judgment and clean data rather than a regulatory deliverable.

What does a Target ID and validation CRO actually do?

The menu varies by target class and by how much is already known, but a strong Target ID and validation CRO typically covers the work below. Most programs use several of these in sequence, starting with the cheapest genetic evidence and moving toward functional confirmation only when the early signal holds.

Two distinctions are worth pinning down with any supplier before you scope. First, genetic validation (does human data link this target to the disease) versus functional validation (does perturbing it in a model change the phenotype) answer different questions, and you usually want both. Second, druggability assessment, whether the target has a tractable binding pocket, a surface antibody can reach, or a degradable handle, decides whether a validated target is even worth a screening campaign. A target can be biologically real and still not be drugged in your chosen modality.

  • Target identification: literature and pathway mining, omics and differential-expression analysis (RNA-seq, proteomics), and disease-network analysis to nominate candidate targets.
  • Genetic association and human evidence: GWAS, Mendelian and rare-disease genetics, eQTL and Open Targets-style scoring to check the target-to-disease link holds in people, not just a model.
  • CRISPR functional validation: knockout, CRISPRi knockdown, and CRISPRa overexpression, including arrayed and pooled screens, to test whether perturbing the target changes the disease-relevant phenotype.
  • RNAi and antisense knockdown: siRNA and shRNA studies as an orthogonal method to confirm a CRISPR result rather than relying on one technology.
  • Target-engagement and mechanism: CETSA, reporter assays, and pathway readouts that show the target is actually being hit and that the downstream biology responds.
  • Druggability and tractability assessment: structural and pocket analysis, modality fit (small molecule, antibody, oligonucleotide, degrader), and an early ligandability read.
  • Model context: in vitro cell lines, patient-derived and primary cells, organoids, and where justified an early in vivo knockout to test whether the target effect carries into a whole organism.

How do you choose a Target ID and validation CRO?

The first filter is fit to your target class and biology, not the size of the logo. A group that runs flawless pooled CRISPR screens in cancer cell lines may be the wrong choice for a CNS target that only behaves in primary neurons or an organoid, and a genetics-heavy informatics shop will not give you the wet-lab functional confirmation you need. Ask for relevant work in your therapeutic area and target class, and confirm the scientists you would actually work with have validated this kind of target before.

Validation depends on orthogonality and honesty more than on volume. A target confirmed by one CRISPR screen is a lead; a target confirmed by CRISPR, an orthogonal RNAi knockdown, a clean rescue, and supportive human genetics is a real program. So weigh a CRO partly on whether they push back, run the confirmatory experiment you did not ask for, and report the targets that failed instead of dressing up a weak signal. In early discovery the cost of a false positive is paid downstream in a screening campaign and chemistry you never should have funded.

Use the checklist below when you compare two or three suppliers against the same written scope.

  • Quality and GxP status: target validation is research-grade and non-GLP, so look for documented SOPs, electronic-notebook practice, reproducibility data (for example screen QC and hit-confirmation rates), and traceable raw data rather than a GLP certificate.
  • Capacity and lead time: confirm current queue and realistic turnaround on a screen and its confirmation, since a great lab booked solid can be slower than a good lab with an open slot.
  • Modality and indication fit: match the CRO to your target class and intended modality (small molecule, antibody, oligonucleotide, degrader), and check they run the right cell systems for your disease, not just an easy immortalized line.
  • Region and regulatory track record: this work rarely files with a regulator, but if any in vivo step or future handoff feeds a regulatory package, confirm the supplier's data standards and where they operate.
  • Data quality and orthogonal confirmation: ask how they confirm a hit (a second method, a rescue, on-target controls for CRISPR), what their assay acceptance criteria are, and whether published or peer-reviewed work backs their methods.
  • IP and confidentiality: settle ownership of validation data and any platform-derived findings in writing, and make sure a CDA is in place before you disclose an undisclosed target you may not want named.

Frequently asked questions

What is the difference between target identification and target validation?
Target identification is nominating the gene, protein, or pathway you think drives the disease, often through omics, literature and pathway mining, and disease-network analysis. Target validation is the work that follows: proving that perturbing that target actually changes the disease biology and that the target is druggable. Identification gives you a candidate; validation tells you whether it is worth a screening campaign and years of chemistry. Most programs spend far more effort on validation, because that is where the real risk reduction happens.
How do CROs validate a drug target?
The strongest validation stacks orthogonal evidence rather than relying on one method. A CRO typically combines human genetic association (GWAS, rare-disease genetics, eQTL) to confirm the target-to-disease link in people, with functional perturbation in a relevant model: CRISPR knockout and CRISPRi knockdown, an orthogonal RNAi or antisense knockdown to confirm the result, on-target controls and a rescue experiment, plus target-engagement and pathway readouts. Where it is justified, an early in vivo knockout tests whether the effect carries into a whole organism. One clean CRISPR screen is a lead, not a validated target.
Does target validation need to be done under GLP?
No. Target identification and validation is research-grade discovery work conducted under good scientific practice, not GLP. GLP is a regulatory quality system for the definitive safety studies that support an IND, which sit much later in the IND-enabling stage. At the validation stage you want reproducibility and traceability instead: qualified assays with documented performance, screen QC, properly controlled CRISPR and RNAi experiments, and clean, auditable data capture. Paying GLP prices for early target work is wasted money.
How long does target identification and validation take?
It varies with the target class and how much human and functional evidence already exists, so treat any single number with caution. A focused validation package built around a few CRISPR and RNAi screens with confirmation often runs a few months. It stretches longer when the disease only behaves in primary cells or organoids, when you add an in vivo knockout step, or when the early signal is mixed and needs more orthogonal work. Scoping the genetics, the functional screens, and any in vivo confirmation as separate milestones with go/no-go gates keeps both the timeline and the spend under control.
How do I assess whether a target is druggable?
Druggability, or tractability, asks whether a validated target can actually be hit by your intended modality. For small molecules that means a tractable binding pocket and an early ligandability read, often informed by structural and pocket analysis. For antibodies it means a reachable cell-surface or secreted target. Oligonucleotides and degraders open up targets that small molecules cannot touch, which is why modality fit is part of the assessment. A target can be biologically validated and still not be druggable in the modality you planned, so settle this before you commit to a screening campaign.
Who owns the validation data when I outsource target work to a CRO?
Settle this in writing before any work starts. In a well-structured arrangement the buyer owns the validation data and any inventions arising from the funded program. Watch for suppliers with proprietary screening or informatics platforms who may claim rights to platform-derived findings, and confirm how raw data, analysis, and reports get transferred to you. Just as important, get a CDA in place before you disclose an undisclosed target, since the identity of what you are pursuing is itself sensitive at this stage.

Source Target ID & Validation with one contract

Compare transparent quotes from qualified Target ID & Validation CROs, then contract once. Free for buyers.

Compare quotes